000178362 001__ 178362
000178362 005__ 20240229143544.0
000178362 0247_ $$2doi$$a10.1371/journal.pone.0261124
000178362 0247_ $$2pmid$$apmid:34982793
000178362 0247_ $$2altmetric$$aaltmetric:120234941
000178362 037__ $$aDKFZ-2022-00012
000178362 041__ $$aEnglish
000178362 082__ $$a610
000178362 1001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b0
000178362 245__ $$aSurvival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years.
000178362 260__ $$aSan Francisco, California, US$$bPLOS$$c2022
000178362 3367_ $$2DRIVER$$aarticle
000178362 3367_ $$2DataCite$$aOutput Types/Journal article
000178362 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1651657185_5876
000178362 3367_ $$2BibTeX$$aARTICLE
000178362 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000178362 3367_ $$00$$2EndNote$$aJournal Article
000178362 520__ $$aSurvival has improved in bladder cancer but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed survival in urothelial cancer (UC, of which vast majority are bladder cancers) in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database. Finland and Sweden are neighboring countries with largely similar health care systems but higher economic resources and health care expenditure in Sweden. We present results on 1- and 5-year relative survival rates, and additionally provide a novel measure, the difference between 1- and 5-year relative survival, indicating how well survival was maintained between these two periods. Over the 50-year period the median diagnostic age has increased by several years and the incidence in the very old patients has increased vastly. Relative 1- year survival rates increased until early 1990s in both countries, and with minor gains later reaching about 90% in men and 85% in women. Although 5-year survival also developed favorably until early 1990s, subsequent gains were small. Over time, age specific differences in male 1-year survival narrowed but remained wide in 5-year survival. For women, age differences were larger than for men. The limitations of the study were lack of information on treatment and stage. In conclusion, challenges are to improve 5-year survival, to reduce the gender gap and to target specific care to the most common patient group, those of 70 years at diagnosis. The most effective methods to achieve survival gains are to target control of tobacco use, emphasis on early diagnosis with prompt action at hematuria, upfront curative treatment and awareness of high relapse requiring regular cystoscopy follow up.
000178362 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000178362 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000178362 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000178362 7001_ $$aHemminki, Akseli$$b2
000178362 7001_ $$aLjungberg, Börje$$b3
000178362 7001_ $$aHemminki, Otto$$b4
000178362 773__ $$0PERI:(DE-600)2267670-3$$a10.1371/journal.pone.0261124$$gVol. 17, no. 1, p. e0261124 -$$n1$$pe0261124 -$$tPLOS ONE$$v17$$x1932-6203$$y2022
000178362 909CO $$ooai:inrepo02.dkfz.de:178362$$pVDB
000178362 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000178362 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000178362 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000178362 9141_ $$y2022
000178362 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-02-04
000178362 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000178362 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000178362 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000178362 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-02-04
000178362 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-02-04
000178362 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPLOS ONE : 2021$$d2022-11-16
000178362 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-16
000178362 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-16
000178362 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-04-12T10:14:32Z
000178362 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-04-12T10:14:32Z
000178362 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-04-12T10:14:32Z
000178362 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-16
000178362 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-16
000178362 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-16
000178362 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-16
000178362 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-16
000178362 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2022-11-16
000178362 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-16
000178362 9201_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000178362 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x1
000178362 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x2
000178362 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000178362 980__ $$ajournal
000178362 980__ $$aVDB
000178362 980__ $$aI:(DE-He78)C050-20160331
000178362 980__ $$aI:(DE-He78)C020-20160331
000178362 980__ $$aI:(DE-He78)B062-20160331
000178362 980__ $$aI:(DE-He78)HD01-20160331
000178362 980__ $$aUNRESTRICTED